Medigen Vaccine Biologics Corp.
Medigen Vaccines Biologics Corp. is dedicated to developing and mass-producing vaccines and biopharmaceuticals. With PIC/S GMP certification, the company specializes in cell culture technology and has the capacity for large-scale vaccine production. It focuses on global and regional infectious diseases, including COVID-19, enteroviruses, and dengue fever, aiming to become a leader in the vaccine and biopharmaceutical industry. The company emphasizes quality, innovation, and social responsibility, contributing to global health and sustainable development.
Industries
Nr. of Employees
small (1-50)
Medigen Vaccine Biologics Corp.
115 Taipei City, Nangang District, Zhongxiao East Road, Section 7, No. 508, 4F, Taiwan (R.O.C.)
Patents
Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US-12296002-B2
View Details
Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US-12296002-B2
View DetailsProducts
Enterovirus A71 vaccine (candidate)
Parenteral vaccine candidate targeting Enterovirus A71 developed with clinical data including infant cohorts; intended for prevention of EV-A71-associated disease.
Quadrivalent seasonal influenza vaccine (QIV)
Licensed quadrivalent seasonal influenza vaccine formulation obtained via technology licensing for local distribution.
Tetravalent dengue vaccine (technology-transferred candidate)
Development of a tetravalent dengue vaccine candidate derived from externally licensed live-attenuated vaccine technology.
RSV monoclonal antibody biosimilar development
Collaborative development program for RSV-targeting monoclonal antibody biosimilars conducted within an international consortium framework.
Protein-subunit COVID-19 vaccine (recombinant S-2P) candidate
Protein subunit vaccine candidate based on a recombinant stabilized spike (S-2P) antigen developed via technology transfer for COVID-19 prevention.
Enterovirus A71 vaccine (candidate)
Parenteral vaccine candidate targeting Enterovirus A71 developed with clinical data including infant cohorts; intended for prevention of EV-A71-associated disease.
Quadrivalent seasonal influenza vaccine (QIV)
Licensed quadrivalent seasonal influenza vaccine formulation obtained via technology licensing for local distribution.
Tetravalent dengue vaccine (technology-transferred candidate)
Development of a tetravalent dengue vaccine candidate derived from externally licensed live-attenuated vaccine technology.
RSV monoclonal antibody biosimilar development
Collaborative development program for RSV-targeting monoclonal antibody biosimilars conducted within an international consortium framework.
Protein-subunit COVID-19 vaccine (recombinant S-2P) candidate
Protein subunit vaccine candidate based on a recombinant stabilized spike (S-2P) antigen developed via technology transfer for COVID-19 prevention.
Services
Commercial-scale production of vaccine bulk and finished doses at a PIC/S GMP-certified facility to support supply and distribution.
Structured licensing, technology transfer and alliance support with international research institutes and public-health organizations for vaccine and biologic development.
Design and operational execution of Phase I–III clinical trials including randomized, double-blind and immunobridging studies across multiple centers.
Neutralization and serology testing to measure vaccine-induced antibody responses and variant neutralization.
Commercial-scale production of vaccine bulk and finished doses at a PIC/S GMP-certified facility to support supply and distribution.
Structured licensing, technology transfer and alliance support with international research institutes and public-health organizations for vaccine and biologic development.
Design and operational execution of Phase I–III clinical trials including randomized, double-blind and immunobridging studies across multiple centers.
Neutralization and serology testing to measure vaccine-induced antibody responses and variant neutralization.
Expertise Areas
- Vaccine research and development
- Clinical trial management and immunobridging
- Bioprocess development and commercial scale-up
- Regulatory compliance and quality assurance (GMP, CE marking)
Key Technologies
- Cell-culture vaccine manufacturing
- PIC/S GMP manufacturing
- Recombinant protein subunit vaccines (stabilized spike antigens)
- Virus-like particle (VLP) platforms
News & Updates
Medigen Vaccines donated vaccines and supplies to care homes for Valentine's Day.
Encouraging the public to get self-paid flu vaccines to expand community immunity.
Medigen Vaccines issues a legal statement against defamation and false rumors.
Medigen Vaccines signed a cooperation agreement with Substipharm Biologics to expand enterovirus vaccine markets in Southeast Asia.
A successful conference on enteroviruses held jointly with Vietnam Pasteur.
Donated quadrivalent flu vaccines for non-public use in September 2024.
Medigen Vaccines donated vaccines and supplies to care homes for Valentine's Day.
Encouraging the public to get self-paid flu vaccines to expand community immunity.
Medigen Vaccines issues a legal statement against defamation and false rumors.
Medigen Vaccines signed a cooperation agreement with Substipharm Biologics to expand enterovirus vaccine markets in Southeast Asia.
A successful conference on enteroviruses held jointly with Vietnam Pasteur.
Donated quadrivalent flu vaccines for non-public use in September 2024.